SCHEMBL11903340

SCHEMBL11903340

CC(c1nc(N)c2ncn([C@@H]3CCCCO3)c2n1)c1nc2ccc(F)c(C3CC3)c2n1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 2/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ APEX1 P27695 1/20 0.37
▸ PI4KA P42356 1/20 0.37
▸ BLM P54132 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ADCY1 Q08828 1/20 0.37
▸ PI4K2B Q8TCG2 1/20 0.37
▸ PI4K2A Q9BTU6 1/20 0.37
▸ PI4KB Q9UBF8 1/20 0.37
▸ CYP2C19 P33261 2/20 0.36
▸ YTHDC1 Q96MU7 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11903338 1.00 CYP2C9 (0.37) CYP2C9HSD17B10ALDH1A1TP53NFKB1
SCHEMBL11903148 0.81 CYP2C19 (0.37) CYP2C9HSD17B10ALDH1A1TP53NFKB1
SCHEMBL11902087 0.81 NPC1 (0.48) CYP2C9HSD17B10ALDH1A1TP53NFKB1
SCHEMBL11903145 0.81 CYP2C19 (0.37) CYP2C9HSD17B10ALDH1A1TP53NFKB1
SCHEMBL12472676 0.80 PI4KA (0.36) CYP2C9HSD17B10ALDH1A1TP53NFKB1
SCHEMBL12471930 0.79 TP53 (0.38) CYP2C9HSD17B10ALDH1A1TP53NFKB1
SCHEMBL11902184 0.72 NPC1 (0.45) CYP2C9HSD17B10ALDH1A1TP53NFKB1
SCHEMBL11901800 0.71 NPC1 (0.51) CYP2C9HSD17B10ALDH1A1TP53NFKB1
SCHEMBL11901795 0.71 NPC1 (0.49) CYP2C9HSD17B10ALDH1A1TP53NFKB1
SCHEMBL12473243 0.70 PI4KA (0.36) CYP2C9HSD17B10ALDH1A1TP53NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 CYP2C9 887/4885HSD17B10 664/4885ALDH1A1 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback